Skip to Main Content

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Conditions

Phase I

Phase I

What is the purpose of this trial?

This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders or cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

  • Trial with
    National Cancer Institute (NCI)
  • Start Date
    11/07/2019
  • End Date
    08/30/2022
Trial Image

For more information about this study, contact:

Stephanie Rosini

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/13/2020
  • Study HIC
    #2000025640